Showing 1-1 of 1 "Movement Disorders"

Status: Enrolling

Investigator: Olga Waln

Study Coordinator: Titilayo Olubajo

Phone: 713.441.3780

This is a multi-center, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on Primidone at baseline who will be allowed 6 weeks of screening to allow for safe ... Read more >